-
Roth Capital Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to Buy
-
Pre-Open Stock Movers 12/10: (SNSS) (RVLT) (COST) Higher; (GDP) (ALLT) (YUM) Lower (more...)
-
Roth Remains Cautious on Sunesis Pharma (SNSS) Pending FDA Visibility on VALOR
-
Roth Affirms Sunesis (SNSS) at 'Neutral'; ASH Presentations May Help Clear Cloudy Outlook
-
Notable Analyst Rating Changes 10/7: (IR) (ADHD) (AAPL) Upgraded; (SNSS) (DE) (CBSH) Downgraded
-
Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Neutral
-
ORR in Sunesis Pharma's (SNSS) Vosaroxin + Decitabine Phase III Improves; Roth Affirms 'Buy' Rating
-
Roth Boosts PT on Sunesis Pharma (SNSS) to $15; Focus Remains on Vosaroxin
-
Roth Capital Keeps Sunesis Pharma (SNSS) at Buy; Hematology Expansion Positive, Eyes Still on VALOR
-
Unusual 11 Mid-Day Movers 09/21: (HALO) (KERX) (SNSS) Higher; (PEIX) (BTH) (KBH) Lower
-
Roth Capital Starts Sunesis Pharmaceuticals Inc. (SNSS) at Buy
-
Unusual 11 Mid-Day Movers 06/06: (ADES) (ZN) (COOL) Higher; (EXEL) (SNSS) (BAP) Lower
-
Morning Movers 06/06: (ADES) (RXII) (ENOC) (COOL) Higher; (SNSS) (OREX) (YMI) (BVN) Lower
-
Morning Movers 3/30: LGL, WEDC, OPXA, FIGI, BNHNA Higher; GNVC, CHGS, ZSTN, HPJ, MPG, OXM Lower

